Inclusion Criteria:  Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study Age ≥18 Karnofsky performance status ≥60 Histological diagnosis of a malignant primary or metastatic tumour Ability to take steroids No contraindication to magnetic resonance imaging (MRI) MRI-diagnosis of a clearly demarcated contrast-enhancing brain metastasis up to 4.0 cm diameter indicated for neurosurgical resection (tumorboard decision). Up to 3 other brain metastases suitable for primary radiosurgery/ stereotactic radiotherapy Survival estimated by primary clinician > 12 months Platelet count > 100/ml, INR < 1.3, Hb > 7.5 g/dL  Exclusion Criteria:  Radiosensitive histology: germ cell tumour, lymphoma, multiple myeloma >10 mm midline shift, effacement of the 4th ventricle or other sign of raised intracranial pressure requiring urgent decompressive surgery More than 4 brain metastases or the diameter of the metastasis for resection >4.0 cm. More than 1 metastasis requiring resection Leptomeningeal disease in the CSF or on MRI (unless localized and can be irradiated then resected with the metastasis) Prior radiation to the brain (SRS/SRT to lesion to be resected and /or WBRT) Prior resection of a primary or secondary brain tumor Prior diagnosis of a non-meningioma brain tumor Prior radionuclide therapy within 30 days Prior anti-VEGF therapy within 6 weeks Unable to tolerate radiosurgery immobilization and treatment Inability to give informed consent Pregnancy or lactation Females of reproductive potential not willing to use effective contraception for at least 6 months after radiotherapy Males of reproductive potential not effective contraception for 3 months after radiotherapy Lack of likely compliance with protocol and follow-up